江南·体育(JN SPORTS)官方网站,江南体育app下载

|
|
EN
  • 业务咨询

    中国:

    Email: marketing@hangzhouaijunshengwu.com

    业务咨询专线:400-780-8018

    (仅限服务咨询,其他事宜请拨打川沙总部电话)

    川沙总部电话: +86 (21) 5859-1500

    海外:

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在线留言×
点击切换
Customer Center
客户中心

研究人员开发了一种高特异性的CDC7抑制剂TAK-931作为临床肿瘤治疗剂,抗肿瘤药效研究通过美迪西进行

2023-07-05
|
访问量:

44.png

Cell division cycle 7 (CDC7) plays important roles in DNA replication. Researchers developed a highly specific CDC7 inhibitor, TAK-931, as a clinical cancer therapeutic agent. The antitumor efficacy studies in PDX models were performed at Medicilon. 

Medicilon has established a complete evalsuation system for preclinical anti-tumor efficacy, and has more than 200 different types of tumor efficacy models.

Reference:

Kenichi Iwai, A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery. Sci Adv. 2021 May 21;7(21):eabf0197. doi: 10.1126/sciadv.abf0197. 


相关新闻
江南·体育(JN SPORTS)官方网站